游离血红蛋白比值作为体外循环心脏术后急性肾损伤的新型生物标志物:随机对照试验的二次分析
该研究为一项随机对照试验的二次分析,纳入对照组110例成人心脏手术患者,探讨体外循环结束时游离血红蛋白比值对术后急性肾损伤的预测价值。结果显示,游离血红蛋白比值>2.23者急性肾损伤发生率、肾脏替代治疗需求和院内死亡率均更高,且该比值预测性能优于尿液生物标志物,联合应用可改善早期预测。
要点
- 体外循环结束时游离血红蛋白比值>2.23与术后急性肾损伤发生率、肾脏替代治疗及院内死亡率升高相关。
- 游离血红蛋白比值预测急性肾损伤的AUC为0.704,优于尿液生物标志物NGAL、NAG和KIM-1。
- 将游离血红蛋白比值加入尿液生物标志物模型可显著改善早期预测的区分度、校准度和净重分类。
核心结论
- 体外循环结束时游离血红蛋白比值可能作为一种新型、广泛适用的急性肾损伤生物标志物,有助于早期检测急性肾损伤。
研究设计与样本
- 该研究为随机对照试验(NCT01802619)的二次分析,纳入对照组110例成人体外循环心脏手术患者。
主要发现
- 调整预设因素后,游离血红蛋白比值与急性肾损伤独立相关。
- 游离血红蛋白比值预测急性肾损伤的AUC为0.704(95%CI 0.592-0.804),准确度为0.714(95%CI 0.579-0.804),优于尿液生物标志物。
临床怎么用
- 对于体外循环心脏手术患者,可在体外循环结束时检测游离血红蛋白并计算比值,辅助早期识别急性肾损伤高风险患者。
- 游离血红蛋白比值可作为尿液生物标志物的补充,联合使用可能提高早期预测效能。
局限性
- 该研究为探索性、假设生成性的回顾性观察研究,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac surgery with cardiopulmonary bypass (CPB) is associated with a high risk of postoperative acute kidney injury (AKI). Due to limitations of current diagnostic strategies, we sought to determine whether free hemoglobin (fHb) ratio (ie, levels of fHb at the end of CPB divided by baseline fHb) could predict AKI after on-pump cardiac surgery. METHODS: This is a secondary analysis of a randomized controlled trial comparing the effect of nitric oxide (intervention) versus nitrogen (control) on AKI after cardiac surgery (NCT01802619). A total of 110 adult patients in the control arm were included. First, we determined whether fHb ratio was associated with AKI via multivariable analysis. Second, we verified whether fHb ratio could predict AKI and incorporation of fHb ratio could improve predictive performance at an early stage, compared with prediction using urinary biomarkers alone. We conducted restricted cubic spline in logistic regression for model development. We determined the predictive performance, including area under the receiver-operating-characteristics curve (AUC) and calibration (calibration plot and accuracy, ie, number of correct predictions divided by total number of predictions). We also used AUC test, likelihood ratio test, and net reclassification index (NRI) to compare the predictive performance between competing models (ie, fHb ratio versus neutrophil gelatinase-associated lipocalin [NGAL], N-acetyl-β-d-glucosaminidase [NAG], and kidney injury molecule-1 [KIM-1], respectively, and incorporation of fHb ratio with NGAL, NAG, and KIM-1 versus urinary biomarkers alone), if applicable. RESULTS: Data stratified by median fHb ratio showed that subjects with an fHb ratio >2.23 presented higher incidence of AKI (80.0% vs 49.1%; P = .001), more need of renal replacement therapy (10.9% vs 0%; P = .036), and higher in-hospital mortality (10.9% vs 0%; P = .036) than subjects with an fHb ratio ≤2.23. fHb ratio was associated with AKI after adjustment for preestablished factors. fHb ratio outperformed urinary biomarkers with the highest AUC of 0.704 (95% confidence interval [CI], 0.592-0.804) and accuracy of 0.714 (95% CI, 0.579-0.804). Incorporation of fHb ratio achieved better discrimination (AUC test, P = .012), calibration (likelihood ratio test, P < .001; accuracy, 0.740 [95% CI, 0.617-0.832] vs 0.632 [95% CI, 0.477-0.748]), and significant prediction increment (NRI, 0.638; 95% CI, 0.269-1.008; P < .001) at an early stage, compared with prediction using urinary biomarkers alone. CONCLUSIONS: Results from this exploratory, hypothesis-generating retrospective, observational study shows that fHb ratio at the end of CPB might be used as a novel, widely applicable biomarker for AKI. The use of fHb ratio might help for an early detection of AKI, compared with prediction based only on urinary biomarkers.
引用
- Hu J, Rezoagli E, Zadek F, et al. Free Hemoglobin Ratio as a Novel Biomarker of Acute Kidney Injury After On-Pump Cardiac Surgery: Secondary Analysis of a Randomized Controlled Trial. Anesth Analg. 2021. PMID: 33481401. doi:10.1213/ANE.0000000000005381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。